ArticlePeerJ2025
The acidic latex protein from
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hev b5 is a unique acidic protein identified as an allergen in natural latex and latex gloves, known for stimulating histamine release from human basophils sensitized with serum from latex-allergic individuals. It is rich in glutamic acid and proline residues arranged in repeated motifs. The protein's unusual amino acid composition includes 48% negatively charged residues and 13% positively charged residues. Methods: The recombinant form of Hev b5 (rHev b5) was produced in Results: rHev b5 exhibited significant chitinase activity and demonstrated substantial antibacterial effects against both Gram-positive and Gram-negative bacteria. The antibacterial activity was notably enhanced in the presence of zinc or calcium ions, suggesting that rHev b5 binds to microbial membranes through metal ion-mediated cationic salt bridges, leading to cell lysis and microbial death. Conclusion: Antimicrobial properties and chitinase activity of Hev b5 underline its potential as an anionic antimicrobial peptide, offering both antifungal and antibacterial defenses. These findings position Hev b5 as a promising candidate for further research in antimicrobial peptide applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.